ZOLL Respicardia, Inc.

Founded in 2006 and acquired by ZOLL in 2021, Respicardia is a leader in technologies that address the unmet needs of people with Central Sleep Apnea (CSA). CSA results from the brain’s inability to send appropriate signals to the respiratory muscles to stimulate breathing during sleep. CSA is a serious breathing disorder that disrupts the normal breathing pattern and negatively affects quality of life and overall health.¹ The remedē System, which received U.S. Food and Drug Administration (FDA) approval in October 2017, is an implantable system that treats the harmful effects of CSA by restoring a more normal breathing pattern during sleep.²